文献速递湿疹皮炎与荨麻疹

Eblasakimab治疗中重度特应性皮炎1b期多剂量递增研究

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study.
PubMed 文献 · J Am Acad Dermatol · 2023-10-20

该1b期随机双盲研究纳入52例中重度特应性皮炎成人患者,每周皮下注射eblasakimab 200、400或600 mg或安慰剂共8周。主要终点为治疗中出现的不良事件发生率,安慰剂组47%、eblasakimab组71%,多为轻中度且未导致停药。

要点

  • Eblasakimab阻断IL-4和IL-13经2型受体信号传导。
  • 治疗中出现的不良事件安慰剂组47%、eblasakimab组71%,多为轻中度。

核心结论

  • 中重度特应性皮炎成人患者接受eblasakimab治疗耐受性良好,且较安慰剂有显著临床改善。

研究设计与样本

  • 1b期随机双盲研究,52例中重度特应性皮炎成人患者每周皮下注射eblasakimab 200、400或600 mg或安慰剂共8周。
  • 主要终点为治疗中出现的不良事件发生率。

主要发现

  • 治疗中出现的不良事件安慰剂组47%、eblasakimab组71%,多为轻中度且未导致研究中止。
  • 其他关键次要医生报告和患者报告终点均达到。

关键数值与推荐

  • EASI较基线改善至少50%、75%或90%为次要终点。
  • 峰值瘙痒数字评定量表评分较基线百分比变化为次要终点。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 需要更长期研究确认eblasakimab在特应性皮炎患者中的安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eblasakimab, an interleukin (IL)-13 receptor α1 antagonist, blocks IL-4 and IL-13 signaling through the type 2 receptor. OBJECTIVE: The safety and efficacy of eblasakimab was evaluated in adults with moderate-to-severe atopic dermatitis (AD). METHODS: In this phase 1b randomized, double-blinded study, 52 patients with moderate-to-severe AD received weekly subcutaneous injections of eblasakimab 200, 400, or 600 mg, or placebo for 8 weeks. Primary outcome was the incidence of treatment-emergent adverse events. Secondary outcomes included percentage change in the Eczema Area and Severity Index from baseline; Eczema Area and Severity Index improvement of at least 50%, 75%, or 90% from baseline; and percentage change in the peak-pruritus numeric rating scale score from baseline. RESULTS: Treatment-emergent adverse events were reported in 47% placebo and 71% eblasakimab patients; most were considered mild or moderate and did not lead to study discontinuation. At week 8 eblasakimab 600 mg showed statistically significant improvement in mean percentage change in Eczema Area and Severity Index versus placebo (-65% vs -27%, P = .014). Other key secondary physician- and patient-reported end points were met. LIMITATIONS: Longer studies are required to confirm eblasakimab safety and efficacy in AD patients. CONCLUSIONS: Treatment of adults with moderate-to-severe AD with eblasakimab was well-tolerated and associated with significant clinical improvements versus placebo.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Veverka KA, Thng STG, Silverberg JI, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2023. PMID: 37866456. doi:10.1016/j.jaad.2023.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。